Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Needs Newer Drugs To Control Diabetes Surge: IFPMA

This article was originally published in PharmAsia News

Executive Summary

A new report sheds light on the unusually low penetration of newer antidiabetic therapies in China, despite their additional therapeutic benefits, and the reasons behind the wider use of insulins and older oral glucose-lowering drugs. Poor monitoring and disease management may further worsen the situation in a country that already has the largest diabetic population in the world, it warns.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts